Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 15;29:42. doi: 10.1186/s12929-022-00824-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — The clinical importance of KRT17 as a prognostic marker in OSCC. A Heatmap analysis of differentially-expressed genes from cDNA microarrays data that were derived from OC3IV (left panel) and OC3 (right panel) OSCC cells. B Datamining analysis of KRT17 mRNA expression in the adjacent normal tissues (N) and OSCC tumor tissues (T) from Oncomine database. C Representative images of IHC staining for the KRT17 protein expression were shown using 3-level pathological ranking of weak, moderate and strong from a set of commercial tissue arrays containing a total of 145 normal and OSCC tissues (top panel). The bottom panel shows a table summarizing statistically the expression differences of KRT17 between normal and OSCC tissues with different pathological stages at I/II or III/IV. D KM plotter survival analysis was performed to examine KRT17 gene expression in a cohort of 307 Head-neck cancer patients (Oncomine database). E Correlation of KRT17 expression to overall survival rates was determined by performing cDNA microarray with 45 OSCC tumor specimens as described in “Methods”